LifeMD Inc

Stage 2’s advancing trend has been undermined by a decisive support failure below the consolidation zone, with price breaking below rising EMAs on heavy volume and RSI rolling over. This behavior shifts the medium-term bias to bearish and aligns with the long-term downtrend, favoring a sell-side posture now.

• ↑Q1 2025 telehealth revenue rose 70% YoY to $65.7M, led by weight management
• ↑Active subscribers climbed 22% YoY to 290K, driving recurring revenue growth
• ↓Negative earnings yield and weak profitability raise doubts on return potential